Natixis Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 67.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,663 shares of the medical research company’s stock after selling 106,774 shares during the quarter. Natixis Advisors LLC’s holdings in IQVIA were worth $9,285,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Sowell Financial Services LLC acquired a new stake in IQVIA during the 1st quarter valued at approximately $305,000. Mather Group LLC. grew its position in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after acquiring an additional 350 shares in the last quarter. Park Avenue Securities LLC grew its position in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after acquiring an additional 1,562 shares in the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after acquiring an additional 566 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after acquiring an additional 3,398 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
Insiders Place Their Bets
In other news, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on IQVIA
IQVIA Stock Up 0.3%
Shares of IQVIA stock opened at $182.97 on Tuesday. The business’s fifty day moving average price is $163.03 and its two-hundred day moving average price is $169.60. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $31.10 billion, a P/E ratio of 26.48, a PEG ratio of 2.00 and a beta of 1.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the previous year, the business earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Five stocks we like better than IQVIA
- Comparing and Trading High PE Ratio Stocks
- Analysts Make a Quantum Bet on D-Wave’s Cryogenic Packaging
- How to Effectively Use the MarketBeat Ratings Screener
- Traders Turn Bullish on Housing Stocks Again—3 Leading the Way
- 3 Monster Growth Stocks to Buy Now
- Onsemi’s August Pullback Is a Signal to Buy for Tech Investors
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.